Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data


ÜSKÜDAR CANSU D., ÜSKÜDAR TEKE H., TEMEL T., Erturk A., Kahraman O., KORKMAZ C.

JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, cilt.111, sa.3, ss.262-269, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 111 Sayı: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.jnma.2018.10.003
  • Dergi Adı: JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.262-269
  • Anahtar Kelimeler: Ankylosing spondylitis, Anti-TNF-alfa, Paradoxical adverse events, Inflammatory bowel disease, NECROSIS FACTOR THERAPY, JUVENILE IDIOPATHIC ARTHRITIS, EXTRAARTICULAR MANIFESTATIONS, GUT INFLAMMATION, ADVERSE EVENTS, NEW-ONSET, SPONDYLOARTHROPATHIES
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: The aim of this study was to determine whether there is any association with anti-tumor necrosis factor (TNF) agent administration and development of new-onset inflammatory bowel disease (IBD) in ankylosing spondylitis (AS) patients.